Spotlight
About
News
CME/CE
Subscribe
Partnerships
SMFM Consult Series 61: Anticoagulation in pregnant patients with cardiac disease
View the latest recommendations from the Society for Maternal-Fetal Medicine on anticoagulation in pregnant patients with cardiac disease.
Lifelong therapeutic anticoagulation is a principal component of the medical management of mechanical heart valves to prevent valve thrombosis.
Anticoagulation regimens indicated outside of pregnancy for patients with mechanical valves should be continued during pregnancy with the possibility of modifications based on the type of valve, the trimester of pregnancy, individual risk tolerance, and circumstances around the time of delivery. The purpose of this document is to provide recommendations regarding the management of anticoagulation for common cardiac conditions complicating pregnancy, including mechanical heart valves, atrial fibrillation, systolic heart failure, and congenital heart disease.
Recent Videos
Related Content
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022Podcast
In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Racial disparities based on delivery hospital quality reported
March 24th 2025Article
A new study found that Black and American Indian birthing individuals in the United States are more likely to deliver at lower-quality hospitals than White patients, highlighting systemic health care inequities.
Read More
August 20th 2021
Podcast
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
sFLT1/PLGF ratio may improve risk stratification for birth outcomes
March 17th 2025Article
A recent study suggests that the soluble fms-like tyrosine kinase 1 to placental growth factor ratio can help predict clinical deterioration, intrapartum fetal distress, and mode of delivery, offering valuable insights for patient counseling and labor management.
Read More
